A New Trial Combining Provenge with A New Investigational Treatment to Enhance Survival

I have written much about the need to begin studies of both timing and combining of the many new treatments we have recently developed for the treatment of advanced prostate cancer. With the FDA approval of Provenge, Zytiga, Jevtana, Xtandi and hopefully in the near future Radium-223 Dichloride (Alpharadin) we have many new treatment options available for men with advanced prostate cancer. Among the many questions we are now faced with is what would happen if we found ways to combine these new treatments? What are the best combinations? We also need to ask what is the best way to [...]